Daclizumab

Drug Profile

Daclizumab

Alternative Names: BIIB-019; DAC HYP; Dacliximab; Daclizumab high-yield process; Daclizumab HYP; HAT antibody; Humanised anti-Tac antibody; R35; RO 247375; SMART anti-Tac antibody; Zenapax; Zinbryta

Latest Information Update: 12 Dec 2016

Price : $50

At a glance

  • Originator PDL BioPharma
  • Developer AbbVie; Biogen; PDL BioPharma
  • Class Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Interleukin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis; Renal transplant rejection
  • Discontinued Asthma; Graft-versus-host disease; Haematological malignancies; Immune-mediated uveitis; Liver transplant rejection; Psoriasis; Tropical spastic paraparesis; Type 1 diabetes mellitus; Ulcerative colitis

Most Recent Events

  • 09 Dec 2016 Registered for Multiple sclerosis (Recurrent) in Canada (SC)
  • 15 Sep 2016 Interim efficacy data from the phase III trial in Multiple sclerosis presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2016)
  • 14 Sep 2016 Adverse events and immunogenecity data from the phase III EXTEND trial in Multiple sclerosis presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top